226 related articles for article (PubMed ID: 36120314)
1. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.
Perna A; Ruggiero B; Podestà MA; Perico L; Orisio S; Debiec H; Remuzzi G; Ruggenenti P
Front Pharmacol; 2022; 13():958136. PubMed ID: 36120314
[TBL] [Abstract][Full Text] [Related]
2. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
[TBL] [Abstract][Full Text] [Related]
3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
4. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
[TBL] [Abstract][Full Text] [Related]
6. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
7. Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy.
Jurubiță R; Obrișcă B; Sorohan B; Achim C; Micu GE; Mircescu G; Ismail G
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34203607
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in patients with membranous nephropathy and kidney insufficiency.
Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
[No Abstract] [Full Text] [Related]
10. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
11. Anti-phospholipase A2 Receptor Antibody in Differentiation and Prognostication of Membranous Nephropathy.
Suthar KS; Vanikar AV; Patel RD; Kanodia KV; Nigam LA; Gandhi PA; Mehta AH
Saudi J Kidney Dis Transpl; 2022; 33(2):280-287. PubMed ID: 37417180
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
13. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
14. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS
Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509
[TBL] [Abstract][Full Text] [Related]
15. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ; Fervenza FC; Induruwage D; Brenchley PE; Rovin B; Hladunewich MA; Reich HN; Lafayette R; Aslam N; Appel GB; Zand L; Kiryluk K; Liu L; Cattran DC;
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1283-1293. PubMed ID: 37471101
[TBL] [Abstract][Full Text] [Related]
16. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
17. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
18. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function.
Ramachandran R; Prabakaran R; Priya G; Nayak S; Kumar P; Kumar A; Kumar V; Agrawal N; Rathi M; Kohli HS; Nada R
Nephron; 2022; 146(2):138-145. PubMed ID: 34818240
[TBL] [Abstract][Full Text] [Related]
20. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
